
CLAIMS

1. A tartrate salt of Compound (I) represented by the following structural formula:



(I),

wherein the molar ratio between Compound (I) and tartaric acid is 1:1.

2. The tartrate salt of claim 1, wherein the tartrate salt is crystalline.

3. The tartrate salt of claim 1, wherein at least 90% by weight of the tartrate salt is in a single crystalline Form.

4. The tartrate salt of any one of claims 1-3, wherein the tartrate salt is characterized by an X-ray powder diffraction pattern which comprises peaks at 11.9°, 15.4°, 16.9°, and 17.2° ± 0.2 in 2θ.

5. The tartrate salt of any one of claims 1-3, wherein the tartrate salt is characterized by an X-ray powder diffraction pattern which comprises at least three peaks chosen from 11.9°, 15.4°, 16.9°, 17.2°, and 25.6° ± 0.2 in 2θ.

6. The tartrate salt of any one of claims 1-3, wherein the tartrate salt is characterized by an X-ray powder diffraction pattern which comprises peaks at 11.9°, 14.0°, 15.4°, 16.9°, 17.2°, 25.6°, 26.3, and 30.7° ± 0.2 in 2θ.

7. The tartrate salt of any one of claims 1-3, wherein the tartrate salt is characterized by an X-ray powder diffraction pattern which comprises peaks at 11.9°, 14.0°, 15.4°, 16.9°, 17.2°, 22.1°, 25.6°, 26.3, 30.7°, and 34.0° ± 0.2 in 2θ.

8. The tartrate salt of any one of claims 4-7, wherein the tartrate salt is characterized by an X-ray powder diffraction pattern which further comprises peaks at 8.7° and 12.9° ± 0.2 in 2θ.

9. The tartrate salt of any one of claims 1-8, wherein the tartrate salt is characterized by a differential scanning calorimeter (DSC) peak phase transition temperature of 189 ± 2 °C.

10. The tartrate salt of any one of claims 1-9, wherein water uptake is less than 4% of the mass of the tartrate salt at 90% relative humidity (RH) as measured under the following conditions:

i) drying between 0.5 and 1.5 mg of the tartrate salt under a nitrogen atmosphere at 0% relative humidity for 2 hours;

ii) increasing or decreasing the relative humidity in steps of 10% from 0% to 90% then to 0%;

iii) maintaining the relative humidity at each step until the mass change compared to the mass of the original tartrate salt per minute is less than 0.01 (%/min), provided that minimum and maximum duration time at each step is 10 minutes and 180 minutes, respectively; and

iv) measuring the mass of the tartrate salt at 90% relative humidity and wherein steps i)-iv) are carried out at 25 ^{o}C.

11. The tartrate salt of claim 10, wherein water uptake is less than 1% of the mass of the tartrate salt at 90% relative humidity (RH).

12. The tartrate salt of any one of claims 1-11, wherein water uptake is less than 1% of the mass of the tartrate salt at 30% relative humidity (RH) as measured under following conditions:

i) drying between 0.5 and 1.5 mg of the tartrate salt under a nitrogen atmosphere at 0% relative humidity for 2 hours;

ii) increasing or decreasing the relative humidity in steps of 10% from 0% to 90% then to 0%;

iii) maintaining the relative humidity at each step until the mass change compared to the mass of the original tartrate salt per minute is less than 0.01 (%/min), provided that minimum and maximum duration time at each step is 10 minutes and 180 minutes, respectively; and

iv) measuring the mass of the tartrate salt at 30% relative humidity and wherein steps i)-iv) are carried out at 25 ^{o}C.

13. The tartrate salt of claim 12, wherein water uptake is less than 0.1% of the mass of the tartrate salt at 30% relative humidity (RH).

14. A pharmaceutical composition comprising the tartrate salt of any one of claims 1-13, and a pharmaceutically acceptable carrier or diluent.

15. Use of the tartrate salt of any one of claims 1-13 or the pharmaceutical composition of claim 14 in the preparation of medicament for treating a subject with cancer.

16. Use of the tartrate salt of any one of claims 1-13 or the pharmaceutical composition of claim 14, and a second anti-cancer treatment (*e.g.*, a chemotherapeutic agent, a targeted therapeutic agent, radiation or surgery) in the preparation of medicament for treating a subject with cancer.

17. Use of the tartrate salt of any one of claims 1-13 or the pharmaceutical composition of claim 14, and an immunomodulatory agent such as a checkpoint inhibitor (*e.g.*, anti-PD-1 antibody, anti-CTLA4 antibody or anti-PD-L1 antibody) or an inhibitor of tryptophan oxidation (*e.g.* IDO1, IDO2 or TDO2 inhibitor) in the preparation of medicament for treating a subject with cancer.